Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standardized Antihypertensive Treatment Protocol Trial
NCT06790927Not yet recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of amlodipine, irbesartan and hydrochlorothiazide in hypertension (HTN) (2 arms), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Control rate of clinical blood pressure at 6 months. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
amlodipineirbesartanhydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06790927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06790927.